Signadori Bio joins The HIVE Innovation Center to accelerate the development of its immunotherapies
Villejuif, 02/04/2026 – Kadans Science Partner announces the arrival of Signadori Bio within the Innovation Center of The HIVE, its building of laboratories and offices dedicated to life sciences, located on the Campus Grand Parc in Villejuif.
A differentiated approach to cancer immunotherapy
Signadori Bio is developing an innovative cell therapy approach based on the use of genetically modified monocytes for the treatment of solid tumors. By targeting key mechanisms of the innate immune system, the company aims to overcome some of the limitations of current immunotherapies and improve their effectiveness in complex oncology indications. Created in 2025 as part of the Biovelocita program, a partnership between Sofinnova Partners and Institut Gustave Roussy, the company benefits from the support of the Biovelocita II fund (€165M) and investors such as Invivo Partners.
The Innovation Center of The HIVE: an environment suited to biotechs in a structuring phase
Designed to meet the specific needs of start-ups and biotechnology companies, this space provides fully operational laboratories and offices, integrated into a flexible service offering to facilitate their installation and daily operations.
Beyond the infrastructure, this approach offers young companies a framework conducive to their development, enabling them to gain visibility and progress within a structured innovation ecosystem.
A strategic presence within the Campus Grand Parc in Villejuif
Located south of Paris, the Campus Grand Parc in Villejuif is a leading hub for oncology and life sciences, bringing together hospitals, research institutes and major academic players. This environment offers Signadori Bio privileged access to a dense scientific ecosystem that supports translational research and partnerships.
“Joining The HIVE Innovation Center marks a defining milestone for Signadori Bio.” explain, Selwyn Ho, CEO of Signadori Bio “Establishing ourselves at the heart of the Campus Grand Parc in Villejuif gives us access to an exceptional scientific and clinical ecosystem, right alongside the key players driving oncology research forward. This is exactly the environment we need to accelerate the development of our monocyte reprogramming platform and bring our ambition to life: transforming the treatment of solid tumors.”
“We are very proud to welcome Signadori Bio as the first company of the Innovation Center, which we designed for companies like theirs, and we wish them great success, as well as all future companies supported by the Biovelocita fund,” says Elise COLLA, Commercial Director France at Kadans Science Partner.
More info about the Innovation Center
More info about Campus Grand Parc
